Pediatric Endocrinology and Diabetology Unit, Children's Hospital, University Hospital of Nancy, France.
Department of Allergology, Children's Hospital, University Hospital of Nancy, France.
Diabetes Res Clin Pract. 2023 Oct;204:110922. doi: 10.1016/j.diabres.2023.110922. Epub 2023 Sep 26.
To evaluate the incidence of the skin reactions secondary to continuous subcutaneous insulin infusion (CSII) or continuous glucose monitoring (CGM), sensors and the characteristics of affected children with type 1 diabetes.
An observational, retrospective, single-centre study included 198 children with type 1 diabetes, (46% girls, mean age 11.75 years). A standardised questionnaire was completed with the patient during current care to evaluate the skin reactions (mean and percentage), the type of reaction, their impact and the treatment) and the characteristics of affected children with univariate and multivariate analysis.
Sixty-seven children (33.8%) reported active skin reactions: 45 children with CSII (30.4%) and 46 with CGM (23.5%). Children with skin reactions were younger (mean age 10.6 yo versus 12.34 yo, p < 0.05), with a younger age at the diagnosis of diabetes (5.59 yo versus 7.08 yo, p < 0.05). Atopy was more frequent in the group with skin reactions (76.1% versus 54.1% p < 0.05). On multivariate analysis, only the personal history of atopy was associated with skin reactions: OR 2.56 [1.16-5.97] (p < 0.05).
This study confirms the high incidence of skin reactions to adhesive devices used in the treatment of type 1 diabetes in children.
评估连续皮下胰岛素输注（CSII）或连续血糖监测（CGM）、传感器及 1 型糖尿病患儿皮肤反应的特点。
本观察性、回顾性、单中心研究纳入了 198 名 1 型糖尿病患儿（46%为女性，平均年龄 11.75 岁）。通过标准问卷对患者进行当前治疗的评估，包括皮肤反应（平均值和百分比）、反应类型、影响以及治疗，然后进行单变量和多变量分析。
67 名儿童（33.8%）报告有活跃的皮肤反应：45 名接受 CSII（30.4%）和 46 名接受 CGM（23.5%）的儿童。有皮肤反应的儿童年龄更小（平均年龄 10.6 岁比 12.34 岁，p < 0.05），且糖尿病诊断时的年龄更小（5.59 岁比 7.08 岁，p < 0.05）。皮肤反应组更常伴有特应性（76.1%比 54.1%，p < 0.05）。多变量分析显示，仅有特应性个人史与皮肤反应相关：OR 2.56 [1.16-5.97]（p < 0.05）。
本研究证实了儿童使用治疗 1 型糖尿病的粘性装置会出现皮肤反应的高发生率。
